These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38501576)

  • 1. Small-molecule inhibitor HI-TOPK-032 improves NK-92MI cell infiltration into ovarian tumours.
    Deng M; Yang R; Sun Q; Zhang J; Miao J
    Basic Clin Pharmacol Toxicol; 2024 May; 134(5):629-642. PubMed ID: 38501576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.
    Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J
    Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo.
    Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B
    Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
    Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
    Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
    Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
    Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
    [No Abstract]   [Full Text] [Related]  

  • 7. Focused Ultrasound Improves NK-92MI Cells Infiltration Into Tumors.
    Yang C; Du M; Yan F; Chen Z
    Front Pharmacol; 2019; 10():326. PubMed ID: 31057396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis.
    Liu Y; Liu H; Cao H; Song B; Zhang W; Zhang W
    Oncol Rep; 2015 Dec; 34(6):3288-96. PubMed ID: 26503118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoplasmic, nuclear, and total PBK/TOPK expression is associated with prognosis in colorectal cancer patients: A retrospective analysis based on immunohistochemistry stain of tissue microarrays.
    Su TC; Chen CY; Tsai WC; Hsu HT; Yen HH; Sung WW; Chen CJ
    PLoS One; 2018; 13(10):e0204866. PubMed ID: 30286126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.
    Jiang H; Zhang W; Shang P; Zhang H; Fu W; Ye F; Zeng T; Huang H; Zhang X; Sun W; Man-Yuen Sze D; Yi Q; Hou J
    Mol Oncol; 2014 Mar; 8(2):297-310. PubMed ID: 24388357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers.
    Lee DH; Jeong YJ; Won JY; Sim HI; Park Y; Jin HS
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma.
    Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H
    Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells.
    Zhang Q; Zheng F; Chen Y; Liang CL; Liu H; Qiu F; Liu Y; Huang H; Lu W; Dai Z
    Cancer Immunol Res; 2024 May; 12(5):631-643. PubMed ID: 38407902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression.
    Lei B; Liu S; Qi W; Zhao Y; Li Y; Lin N; Xu X; Zhi C; Mei J; Yan Z; Wan L; Shen H
    Histopathology; 2013 Nov; 63(5):696-703. PubMed ID: 24025073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase.
    Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X
    Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.
    Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
    Br J Cancer; 2017 Jan; 116(2):218-226. PubMed ID: 27898655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells.
    Shiozawa M; Chang CH; Huang YC; Chen YC; Chi MS; Hao HC; Chang YC; Takeda S; Chi KH; Wang YS
    BMC Immunol; 2018 Aug; 19(1):27. PubMed ID: 30075754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival.
    Wang MY; Lin ZR; Cao Y; Zheng LS; Peng LX; Sun R; Meng DF; Xie P; Yang JP; Cao L; Xu L; Huang BJ; Qian CN
    Oncotarget; 2016 May; 7(18):26604-16. PubMed ID: 27049917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PBK/TOPK, a proliferating neural progenitor-specific mitogen-activated protein kinase kinase.
    Dougherty JD; Garcia AD; Nakano I; Livingstone M; Norris B; Polakiewicz R; Wexler EM; Sofroniew MV; Kornblum HI; Geschwind DH
    J Neurosci; 2005 Nov; 25(46):10773-85. PubMed ID: 16291951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
    He F; Yan Q; Fan L; Liu Y; Cui J; Wang J; Wang L; Wang Y; Wang Z; Guo Y; Huang G
    Hum Pathol; 2010 Mar; 41(3):415-24. PubMed ID: 19954816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.